05777nam 2201705z- 450 991055754620332120231214133607.0(CKB)5400000000044145(oapen)https://directory.doabooks.org/handle/20.500.12854/69451(EXLCZ)99540000000004414520202105d2020 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierNovel Biomarkers for Heart DiseaseBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20201 electronic resource (420 p.)3-03943-883-2 3-03943-884-0 Cardiac biomarkers such as troponins and natiuretic peptides have made a great impact on clinical decision making as well as improving our understanding of molecular mechanisms of different disease conditions. However, the biomarkers that are currently in use do not reflect all the multiple disease pathways that are involved in a broad spectrum of cardiac disease conditions ranging from acute coronary syndrome, to heart failure (and heart failure with preserved ejection fraction, HFpEF), to pulmonary hypertension or arrhythmias. In this Special Issue, we will provide an overview of the current developments in the field of biomarker research, beginning with research on molecular pathways and cellular communication (e.g., microRNA) up to the clinical use of biomarkers.Medicinebicsscdiet qualityceramidesobesitycardiovascular riskhealthy eating indexcarbohydrate antigen-125heart failureinflammatory markerolder womenbiomarkercardiometabolic diseaseepicardial adipose tissueepicardial fatepicardial fat volumemicroRNAthyroid-stimulating hormonecardiometabolic risksmetabolic syndromehypertensionvery low-density lipoproteinSTIM1SOCEatrial myopathyatrial fibrillationejection fractionsoluble urokinase-type plasminogen activator receptor (suPAR)growth differentiation factor 15 (GDF-15)heart-type fatty acid-binding protein (H-FABP)soluble suppression of tumorigenicity 2 (sST2)acute myocardial infarctionbiomarkerscatestatincoronary artery diseaseheart failure decompensationleft ventricular ejection fractiontroponinNT-proBNPNYHA functional classGDF-15cardiovascular surgeryoperative riskmuscle wastingsarcopeniarenal dysfunctionchronic kidney diseaseaortic diseaseaneurysmmiRNATGF-β pathwayKLF4synthetic phenotypeaortic regurgitationechocardiographymagnetic resonance imagingvena contracta arealongitudinal strainT1 mappingGDF8myostatinAMIceruloplasminH-FABPheart-type fatty acid-binding proteinFABP3fatty acid-binding protein 3HFcardiac biomarkerscardiac magnetic resonance imagingleft ventricular systolic functionmagnetic resonance spectroscopymyocardial triglyceride contentcell adhesion moleculerepeated measurementspregnancy-associated plasma protein-Acohort studiescardiovascular diseasesmitochondrial dysfunctioncirculating cellsPBMCSplateletsoxidative stressreactive oxygen species (ROS)mitochondrial DNA (mtDNA)herat failureliver-type fatty-acid-binding proteinlong-term outcomescardiac intensive care unitsacute kidney injurymyocardial infarctionSTEMIcardiovascular eventscardiovascular deathrisk stratificationsST2Pentraxin-3sudden cardiac deathventricular arrhythmiaventricular tachycardiachronic heart failuresalivasalivary biomarkersCKDCVDPPCIleft ventricular adverse remodellingcirculating miRNAsNAFLDFramingham risk scorerisk predictionsecondary preventionprimary preventionNAFLD fibrosis scoreHFpEFHFrEFsuPARMedicineLichtenauer Michaeledt1287943Lichtenauer MichaelothBOOK9910557546203321Novel Biomarkers for Heart Disease3020593UNINA